This month's profile groups: Treating Traumatic Brain Injury
For acute TBI patients, the lack of any reliable biological markers makes it nearly impossible to design trials with any...
Start-Up Previews (01/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "Treating Traumatic Brain Injury," with profiles of Banyan Biomarkers, NeuroPharma AB, and RemeGenix; and "Can Stents Pull Off a Disappearing Act?," with profiles of Amaranth Medical, Bioabsorbable Therapeutics, and TissueGen Plus these Start-Ups Across Health Care: Design Medical, Kythera Biopharmaceuticals and Plethora Solutions.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
In Partnership with Cerba Research
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
• By
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
• By
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.